Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989;29(4):247-54.
doi: 10.1007/BF00199212.

Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine

Affiliations

Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine

D M Euhus et al. Cancer Immunol Immunother. 1989.

Abstract

Urinary-tumor-associated antigen (U-TAA) is a glycoprotein present in the urine of melanoma patients. Previous studies have addressed the role of U-TAA in immunoprognosis. The present investigation was undertaken to determine whether the administration of whole melanoma cell vaccine (MCV) could induce the formation of anti-(U-TAA) antibodies in melanoma patients. The subjects of this study were stage II and III melanoma patients receiving MCV alone or in conjunction with cyclophosphamide. Anti-(U-TAA) IgM and IgG antibody levels were determined by enzyme immunoassay in sequential serum samples from 15 stage II and III melanoma patients receiving MCV. U-TAA purified from the urine of a melanoma patient was used as a target in this assay. The mean anti-(U-TAA) IgM titer prior to vaccination was similar to that of a non-vaccinated melanoma control group (1:1138 +/- 214, n = 15 vs 1:1334 +/- 254, n = 7; P = 0.375) but prevaccination IgG levels were generally higher than in the control group (1:3984 +/- 602 vs 1:2595 +/- 423; 0.1 greater than P greater than 0.05). While only 6 of the 15 patients demonstrated a rise in levels of IgG antibodies (mean 1:2964 +/- 1047 pre-MCV to 1:9958 +/- 2677 post MCV, P less than 0.01), 11 of the 15 patients demonstrated a greater than twofold rise in their anti-(U-TAA) IgM titers following vaccination (1:1051 +/- 259 pre-MCV to 1:2518 +/- 576 post-MCV; P less than 0.005). In addition, patients with visceral metastases consistently elicited anti-(U-TAA) responses equivalent to those with more limited disease. Concomitant administration of cyclophosphamide did not affect the response rates of peak antibody levels. The possibility that these antibody responses were actually against histocompatibility locus antigens (HLA) (contaminating our U-TAA preparation) was ruled out because the target antigen (U-TAA) was devoid of HLA, and because the induction of anti-(U-TAA) antibodies did not correlate with the induction of anti-HLA antibodies. These results demonstrate augmentation of anti-(U-TAA) IgM and IgG antibodies by immunization with the MCV.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Berd D, Maquire HC, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 1986;46:2572. - PubMed
    1. Burk MW, Saxton RE, Meier SJ, Morton DL. Immune cytolysis of human malignant melanoma by antibody to oncofetal antigen-I (OFA-I). II. Antibody-dependent cell mediated cytotoxicity. Surg Forum. 1980;31:427.
    1. Carrel S, Accolla RS, Carmagnola AL, Mach JP. Common human melanoma-associated antigen(s) detected by monoclonal antibodies. Cancer Res. 1980;40:2523. - PubMed
    1. Cassel WA, Murray DR, Phillips HS. A phase II study on the postsurgical management of stage II malignant melanoma with New Castle Disease Viral Oncolysate. Cancer. 1973;52:856. - PubMed
    1. Chee DO, Gupta RK, Morton DL. Humeral response of melanoma patients to two different tumor-associated antigens. J Surg Oncol. 1983;23:228. - PubMed

Publication types